Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

Inclusion Criteria: Subjects will be eligible if the following criteria are met: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age \> 18 years * Patient related considerations * All patients of both genders will be considered for enrollment. * Disease related considerations * Patients meeting accepted criteria for undergoing corneal transplantation will be considered if peripheral corneal neovascularization exists in 2 or more contiguous clock hours Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from this study: * Pregnancy (positive pregnancy test) * Women seeking to become pregnant * Lactating women * Prior enrollment in the study * Prior glaucoma surgery in the region of the corneal neovascularization * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * Participation in another simultaneous medical investigation or trial